A key advisory panel of the US medicines regulator has voted in favor of providing Emergency Use Authorization (EUA) for BioNTech (Nasdaq: BNTX) and Pfizer’s (NYSE: PFE) coronavirus vaccine.
The outcome was widely anticipated, after briefing notes released before the meeting highlighted the safety and efficacy of the innovative mRNA-based product.
Pfizer stock rose 3% overnight after closing slightly lower. BioNTech stock climbed 3% in extended trade after a 5.5% pop Thursday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze